Other studies [49] have found that the SPI1 inhibitor DB2313 can restore endogenous FTO expression and reduce the tumor burden of GBM, indicating that FTO is a promising new prognostic indicator and therapeutic molecular target for GBM. The gene discussed is FTO; the disease is glioblastoma.